Top Ten most popular articles on Pharmafile.com this week
pharmafile | May 18, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Cancer, FDA, Novartis, Takeda, Trump, brexit, pharma, pharmafile, top ten
The year is flying by – it’s another Friday, and that means another Top Ten run-down.
Perhaps the biggest story this week was that Novartis found itself at the centre of controversy again, as it emerged that the company had paid a massive $1.2 million to Donald Trump’s lawyer Michael Cohen in the hopes of meeting the President to gain some insight into the direction his administration would be likely to move in. But things didn’t go to plan.
However, the most popular story with our readers this week was actually the news that UK MPs are again calling for priority of the pharma industry in Brexit discussions, demanding that the UK be aligned as close as possible to European operations when the time comes to exit the Union.
Check out the week’s ten most popular articles on Pharmafile.com now!
10. Bringing the PRO to fruition
Patient-reported outcomes are becoming increasingly respected and valued by clinical professionals in the pursuit of improving treatment outcomes, but their evolution is not a smooth-sailing affair, as Matt Fellows uncovers.
9. Ipsen receives European first-line approval for Cabometyx
Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced renal cell carcinoma.
8. AZ’s Fasenra stumbles in P3 for COPD
AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up indications to mount a serious challenge – in COPD, at least, that looks more unlikely after the treatment wasn’t able to meet its primary endpoints in a Phase 3 trial.
7. Pharma unfazed by Trump price-reduction proposals
President Trump’s speech on Friday afternoon had been long-anticipated, ever since he was elected and then hammered the pharma industry with talk over how it was “getting away with murder”.
6. How to treat colds? Target the person, not the virus
Researchers from Imperial College London have discovered how to interfere with one of the building blocks that allows the common cold to replicate rapidly in the human body.
5. New cancer clinical trial model promises to cut costs and development time
Researchers from the University of Texas MD Anderson Cancer Center have been developing and testing a new model for the better design and operation of clinical trials into the treatment of cancerous tumours.
4. FDA issues warning letter over potential for poisoning at India plant
The FDA has noted a number of failings at a plant in Gujarat, India, but mostly significantly was the finding that the company had failed to test for diethylene glycol in the components of its drugs.
3. Takeda financials show why the Shire deal was needed
After posting its financials from 2017 and its guidance for the year to come, it’s clear to see why Takeda needed to inject some growth into the company through its mega-merger with Shire.
2. Novartis’ top lawyer retires from role over botched Trump deal
The saga of Novartis’ ill-advised $1.2 million deal with US President Donald Trump’s lawyer Michael Cohen continues to unfold as it emerges that company’s top legal figure, General Counsel Felix Ehrat, has retired from his role in response to the scandal.
1. UK MPs call for Brexit priority over pharma industry
A new report published by the Business, Energy and Industrial Strategy Committee has called for the UK government to ensure that the pharmaceutical industry is aligned as closely as possible to European regulation post-Brexit.
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
